Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical pharmacology and therapy

• Publication date

  2000-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1067/mcp.2000.110977PMID 11103757
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cited by this paper
• Antithrombotic therapy in children.

  2001cited by this paper
• Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.

  1999cited by this paper
• Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone

  1999cited by this paper
• Antithrombotic therapy in children.

  1999cited by this paper
• Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.

  1998cited by this paper
• Enhanced Thrombin Regulation during Warfarin Therapy in Children Compared to Adults

  1998cited by this paper
• Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

  1998cited by this paper
• Guidelines for antithrombotic therapy in pediatric patients.

  1998cited by this paper
• Genetic analysis of CYP2C9 polymorphism in a Japanese population.

  1997cited by this paper
• Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection.

  1997cited by this paper
• Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility.

  1997cited by this paper
• Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.

  1997cited by this paper
• Clinically Important Drug Interactions with Anticoagulants

  1996cited by this paper
• Anticoagulation with Warfarin in Infants and Children

  1996cited by this paper
• Liver volume as a determinant of drug clearance in children and adolescents.

  1995cited by this paper
• Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe.

  1995cited by this paper
• Calculation of child and adult standard liver volume for liver transplantation

  1995cited by this paper
• Lean Body Mass as a Predictor of Drug Dosage

  1994cited by this paper
• Oral Anticoagulation Therapy in Pediatric Patients: a Prospective Study

  1994cited by this paper
• Vitamin K1 metabolism and the production of des-carboxy prothrombin and protein C in the term and premature neonate.

  1993cited by this paper
• Maturation of the hemostatic system during childhood.

  1992cited by this paper
• Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.

  1992cited by this paper
• Vitamin K concentrations in the plasma and liver of surgical patients.

  1990cited by this paper
• Paediatric drug dosing. Bodyweight versus surface area.

  1989cited by this paper
• A formula to estimate the approximate surface area if height and weight be known

  1989cited by this paper
• Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Second Edition

  1987cited by this paper
• Development of the human coagulation system in the full-term infant.

  1987cited by this paper
• In vivo hepatic volume determination using sonography and computed tomography

  1987cited by this paper
• In vivo hepatic volume determination using sonography and computed tomography. Validation and a comparison of the two techniques.

  1985cited by this paper
• Clinical Pharmacology & Therapeutics

  1980cited by this paper
• Reference Japanese man--I. mass of organs and other characteristics of normal Japanese.

  1979cited by this paper
• Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.

  1978cited by this paper
• Bioavailability assessment: methods to estimate total area (AUC O to infinity) and total amount excreted (A infinity e) and importance of blood and urine sampling scheme with application to digoxin.

  1977cited by this paper
• A physiological approach to hepatic drug clearance

  1975cited by this paper
• Commentary: a physiological approach to hepatic drug clearance.

  1975cited by this paper
• Clinical pharmacy and therapeutics

  1975cited by this paper
• Studies on the optical enantiomorphs of warfarin in man.

  1974cited by this paper
• The Extracellular Fluid Volume in Infants and Children

  1954cited by this paper
• Simplification of drug dosage calculation by application of the surface area principle.

  1950cited by this paper
• Standards for the basal metabolism of children from 2 to 15 years of age, inclusive

  1943cited by this paper
• Body Length and Organ Weights of Infants and Children: A Study of the Body Length and Normal Weights of the More Important Vital Organs of the Body between Birth and Twelve Years of Age.

  1933cited by this paper

• Comprehension and practical considerations in pediatric pharmacotherapy: a narrative review

  2025cites this paper
• Hunting potential SIRT2 inhibitors towards cancer treatment: Drug repurposing, molecular dynamics, and binding energy computations.

  2025cites this paper
• Exposure Matching‐Based Pediatric Dose Selection for Drugs with Renal Excretion – Lessons Learned from Pediatric Development of Direct Oral Anticoagulants

  2024cites this paper
• The impact of child-specific characteristics on warfarin dosing requirements

  2024cites this paper
• Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion

  2023cites this paper
• Various Factors Influencing the Enantiomers of Warfarin Pharmacokinetics: A Systematic Review of Population Pharmacokinetics

  2023cites this paper
• Comparison of intravenous ibuprofen pharmacokinetics between Caucasian and Chinese populations using physiologically based pharmacokinetics modeling and simulation.

  2023cites this paper
• More than a small adult brain: Lessons from chemotherapy-induced cognitive impairment for modelling paediatric brain disorders.

  2023cites this paper
• Cytochrome P450 enzymes in the pediatric population: Connecting knowledge on P450 expression with pediatric pharmacokinetics.

  2022cites this paper
• Pharmacogenomics in Children.

  2022cites this paper
• Pediatric therapeutic drug monitoring, toxicology and pharmacogenomics

  2021cites this paper
• Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations

  2021cites this paper
• An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?

  2021cites this paper
• Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model

  2021cites this paper
• Are body surface area based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study

  2021cites this paper
• Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event‐free survival in intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group

  2021cites this paper
• Pharmacokinetics and Pharmacodynamics in the Pediatric Population

  2021cites this paper
• ASSESSMENT OF DRUG UTILIZATION AMONG PEDIATRIC PATIENTS IN PRIVATE CLINIC AND PUBLIC HOSPITAL OF BANGLADESH

  2020cites this paper
• Exposure–response modelling approaches for determining optimal dosing rules in children

  2020cites this paper
• No population left behind: Improving paediatric drug safety using informatics and systems biology

  2020cites this paper
• Pharmacokinetics and pharmacodynamics

  2020cites this paper
• Evaluation of the effects of ontogenetic or maturation functions and chronic heart failure on the model analysis for the dose-response relationship of warfarin in Japanese children

  2019cites this paper
• Scoring criteria for determining the safety of liver resection for malignant liver tumors

  2019cites this paper
• Considerations for Implementing Precision Therapeutics for Children

  2019cites this paper
• A quantitative framework to inform extrapolation decisions in children

  2019cites this paper
• Research on the Effects of Medications in Pregnancy and in Children

  2019cites this paper
• Bridging the gap:using extrapolation to reduce the experimental burden in children

  2018cites this paper
• Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China

  2018cites this paper
• Weight and the vitamin K expoxide reductase 1 genotype primarily contribute to the warfarin dosing in pediatric patients with Kawasaki disease.

  2018cites this paper
• Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis

  2018cites this paper
• UNUSUAL WARFARIN DOSE TO ACHIEVE THERAPEUTIC INR IN A 4-MONTH OLD CHILD: NON-GENETICS RISK FACTORS ARE STILL A CHALLENGE

  2017cites this paper
• Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib

  2017cites this paper
• Adverse Drug Reactions in Children: The Double‐Edged Sword of Therapeutics

  2017cites this paper
• Pharmacogenetics-based warfarin dose prediction algorithm for patients with heart valve replacement in Southeast China

  2017cites this paper
• Personalised dosing of medicines for children

  2017cites this paper
• Dose não usual de varfarina para alcançar rni terapêutica em uma criança de quatro meses: fatores de risco não genéticos ainda são um desafio

  2017cites this paper
• Prescribing practices for pediatric out-patients: A case study of two teaching hospitals in Nigeria

  2017cites this paper
• Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling

  2016cites this paper
• A model analysis for dose-response relationship of warfarin in Japanese children: An introduction of the SIZE parameter.

  2016cites this paper
• Developmental Pharmacology: Impact on Pharmacokinetics and Pharmacodynamics of Drugs

  2016cites this paper
• The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.

  2015cites this paper
• [Understanding and reducing the risk of adverse drug reactions in pediatric patients].

  2015cites this paper
• Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children

  2015cites this paper
• DRUG UTILIZATION STUDY IN THE OUTPATIENT PEDIATRIC DEPARTMENT OF A TERTIARY CARE TEACHING HOSPITAL OF DISTRICT LUCKNOW

  2015cites this paper
• Functional Biomarkers: an Approach to Bridge Pharmacokinetics and Pharmacodynamics in Pediatric Clinical Trials.

  2015cites this paper
• Developmental Regulation of Phase-I Drug Metabolizing Genes in Mouse Liver

  2014cites this paper
• Pharmacokinetics in children with liver disease : can ex vivo obtained population-specific CYP450 characteristics bridge the knowledge gap?

  2014cites this paper
• Key W ords: children dose individualization pharmacogenetics PK/P d models prediction models warfarin

  2014cites this paper
• Pharmacogenetics-based warfarin dosing in children.

  2014cites this paper
• Frequency of CYP2C9 and VKORC1 Gene Polymorphisms and Their Influence on Warfarin Dose in Egyptian Pediatric Patients

  2014cites this paper
• Nanomedicines in the future of pediatric therapy.

  2014cites this paper
• Developmental pharmacokinetics in pediatric populations.

  2014cites this paper
• Characterizing the impact of development on the dose-exposure-response relationship: challenge or opportunity?

  2014cites this paper
• Warfarin pharmacogenomics in children

  2013cites this paper
• Pharmacogenetics of Oral Anticoagulants and Antiplatelets

  2013cites this paper
• Pharmacometric Models for Individualisation of Warfarin in Adults and Children

  2013cites this paper
• Pharmacokinetics and Pharmacodynamics of Anticoagulants in Paediatric Patients

  2013influential citation
• Prediction of heptatic and renal clearance in pediatric populations: A "bottom-up" approach versus "top-down" recognition of covariates

  2013cites this paper
• Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms

  2013cites this paper
• Characterizing variability in warfarin dose requirements in children using modelling and simulation

  2013cites this paper
• Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients.

  2013cites this paper
• Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans

  2013cites this paper
• Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.

  2013cites this paper
• Development and Clinical Trial Design

  2013cites this paper
• DRUG PRESCRIBING PRACTICES IN PAEDIATRIC DEPARTMENT OF A NORTH INDIAN UNIVERSITY TEACHING HOSPITAL

  2012cites this paper
• Investigations of pharmacokinetic challenges in premature infants

  2012cites this paper
• Increased Cyclosporin A Sensitivity In Vivo in Pediatric Renal Transplant Recipients Compared With Adults

  2012cites this paper
• large proportion of the variability in warfarin dose requirement among genotype and patient characteristics explain a CYP 2 C 9 and VKORC

  2012cites this paper
• Beyond Pharmacogenetics

  2012cites this paper
• Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.

  2012cites this paper
• Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology

  2012cites this paper
• Cytostatic drugs in infants: a review on pharmacokinetic data in infants.

  2012cites this paper
• Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid

  2012cites this paper
• Identification of the factors influencing anticoagulation response to warfarin in children

  2012cites this paper
• Age‐Dependent Expression of Human Drug‐Metabolizing Enzymes

  2012cites this paper
• Drug Metabolism and Interactions in Pediatric Patients

  2012cites this paper
• VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

  2012cites this paper
• Development of biomarkers to optimize pediatric patient management: what makes children different?

  2011cites this paper
• Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults

  2011cites this paper
• Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.

  2011cites this paper
• Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation

  2011cites this paper
• Pharmacogenomics of Cardiovascular Drugs and Adverse Effects in Pediatrics

  2011cites this paper
• Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children

  2011cites this paper
• Basics and dynamics of neonatal and pediatric pharmacology.

  2011cites this paper
• Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients.

  2011cites this paper
• Immunosuppression in pediatric liver transplantation: Are little people different?

  2011cites this paper
• Principles of therapeutic drug monitoring.

  2011cites this paper
• Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice

  2011cites this paper
• Ontogeny of hepatic drug metabolizing enzymes in sheep

  2010cites this paper
• The "age" of understanding VKA dose.

  2010cites this paper
• In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.

  2010cites this paper
• Understanding Developmental Pharmacodynamics

  2010cites this paper
• Optimizing Pediatric Dosing: A Developmental Pharmacologic Approach

  2009cites this paper
• Pantoprazole intraveineux aux soins intensifs pédiatriques: un modèle de pharmacocinétique de population

  2009cites this paper
• Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children.

  2009cites this paper
• [Particularities of pharmacotherapy in children. Is there a metamorphosis of "therapeutic orphans"?].

  2009cites this paper
• Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients.

  2009cites this paper
• Mitochondria as a target for novel chemotherapeutic agents based on phenolic acids

  2008cites this paper
• Beyond single nucleotide polimorphism

  2008cites this paper
• Pantoprazole intraveineux aux soins intensifs pédiatriques

  2008cites this paper